BAX
Baxter International Inc. NYSE$17.21
Mkt Cap $8.8B
52w Low $15.73
8.7% of range
52w High $32.68
50d MA $18.10
200d MA $20.84
P/E (TTM)
-9.8x
EV/EBITDA
23.3x
P/B
1.4x
Debt/Equity
1.6x
ROE
-15.6%
P/FCF
30.4x
RSI (14)
—
ATR (14)
—
Beta
0.62
50d MA
$18.10
200d MA
$20.84
Avg Volume
9.5M
About
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care product…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 0.31 | 0.36 | +16.1% | 16.90 | +4.9% | +4.0% | +1.8% | — | — | — | — | — |
| Feb 12, 2026 | BMO | 0.53 | 0.44 | -17.0% | 22.28 | -12.4% | -16.0% | -11.2% | -6.9% | -1.8% | -4.2% | -23.3% | — |
| Oct 30, 2025 | BMO | 0.60 | 0.69 | +15.0% | 22.42 | -15.5% | -14.5% | -17.6% | -18.8% | -20.0% | -19.9% | -14.9% | — |
| Jul 31, 2025 | BMO | 0.60 | 0.59 | -1.7% | 28.05 | -15.3% | -22.4% | -21.7% | -20.0% | -18.6% | -19.8% | -13.8% | — |
| May 1, 2025 | BMO | 0.48 | 0.55 | +13.8% | 31.17 | +3.1% | -1.6% | -1.5% | -2.4% | -4.0% | -1.4% | -5.2% | — |
| Feb 20, 2025 | BMO | 0.53 | 0.58 | +9.8% | 30.82 | +8.0% | +8.5% | +9.7% | +13.8% | +16.6% | +14.4% | +9.0% | — |
| Nov 8, 2024 | BMO | 0.78 | 0.80 | +2.6% | 36.04 | -1.6% | -3.9% | -5.0% | -6.1% | -9.5% | -12.0% | -11.6% | — |
| Aug 6, 2024 | BMO | 0.66 | 0.68 | +2.7% | 34.64 | +1.0% | +6.6% | +5.6% | +8.0% | +7.2% | +6.6% | +12.1% | — |
| May 2, 2024 | BMO | 0.61 | 0.65 | +7.1% | 40.34 | -3.1% | -8.5% | -8.6% | -9.5% | -10.5% | -11.4% | -15.5% | — |
| Feb 8, 2024 | BMO | 0.86 | 0.88 | +2.3% | 39.38 | -1.0% | +2.7% | +0.4% | +2.4% | +0.6% | +0.7% | +10.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $16.68 | $16.66 | -0.1% | -0.2% | -0.4% | +3.4% | +3.7% | +2.8% |
| Mar 11 | Citigroup | Maintains | Neutral → Neutral | — | $17.46 | $17.51 | +0.3% | +3.4% | +3.2% | -0.3% | -2.2% | +0.9% |
| Feb 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.79 | $20.09 | +1.5% | +4.8% | +10.5% | +7.8% | +9.0% | +7.4% |
| Feb 13 | Barclays | Maintains | Overweight → Overweight | — | $18.71 | $18.67 | -0.2% | +5.8% | +10.8% | +16.9% | +14.1% | +15.3% |
| Jan 9 | Barclays | Maintains | Overweight → Overweight | — | $20.69 | $20.90 | +1.0% | +1.8% | -2.6% | -5.0% | -4.1% | -1.5% |
| Dec 2 | Morgan Stanley | Maintains | Underweight → Underweight | — | $19.08 | $18.99 | -0.5% | -1.3% | -1.0% | -3.1% | -2.8% | -4.8% |
| Oct 31 | Citigroup | Maintains | Neutral → Neutral | — | $19.16 | $18.81 | -1.8% | -3.6% | -5.0% | -6.4% | -6.3% | -6.2% |
| Oct 31 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.16 | $18.81 | -1.8% | -3.6% | -5.0% | -6.4% | -6.3% | -6.2% |
| Oct 31 | Argus | Downgrade | Buy → Hold | — | $19.16 | $18.81 | -1.8% | -3.6% | -5.0% | -6.4% | -6.3% | -6.2% |
| Oct 31 | UBS | Maintains | Neutral → Neutral | — | $19.16 | $18.81 | -1.8% | -3.6% | -5.0% | -6.4% | -6.3% | -6.2% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Vafa Jamali's appointment as director signals potential strategic shifts in governance and decision-making, warranting investor attention to board composition changes affecting corporate direction and oversight quality.
Apr 6
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new executive at Baxter or Inogen with a $525,000 base salary and 70% bonus potential signals leadership continuity, but investors should monitor whether this hire strengthens operational execution or represents reactive replacement.
Mar 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Baxter is communicating adjusted financial metrics to shareholders, signaling management's focus on operational performance rather than reported results, which typically indicates confidence in underlying business strength despite potential accounting headwinds.
Mar 19
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Baxter International made a material announcement on March 16, 2026, requiring SEC disclosure, likely signaling executive or strategic news that could impact investor expectations and stock valuation.
Mar 16
8-K · 5.02
!!! Very High
Baxter International Inc. -- 8-K 5.02: Executive Change
Baxter International appointed Michael R. McDonnell as Executive Vice President effective February 13, 2026, signaling internal leadership development and potential changes to executive responsibilities.
Feb 12
Data updated apr 24, 2026 8:36pm
· Source: massive.com